| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1004: Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion |
|
Medicine details |
|
| Medicine name | faricimab (Vabysmo) |
| Formulation | 120 mg/mL solution for injection |
| Reference number | 5178 |
| Indication | Treatment of visual impairment caused by macular oedema after retinal vein occlusion |
| Company | Roche |
| BNF chapter | Eye |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 01/08/2024 |
| NICE guidance | |